Omnicell, Inc. (NASDAQ:OMCL) VP Jorge R. Taborga sold 20,719 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $50.98, for a total transaction of $1,056,254.62. Following the completion of the transaction, the vice president now directly owns 53,270 shares in the company, valued at $2,715,704.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Omnicell, Inc. (NASDAQ OMCL) traded up 0.51% during midday trading on Friday, hitting $49.55. 244,016 shares of the stock were exchanged. Omnicell, Inc. has a 12-month low of $30.35 and a 12-month high of $51.97. The firm has a 50 day moving average of $46.10 and a 200-day moving average of $41.60. The stock’s market cap is $1.86 billion.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.02. The business had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.38 EPS. On average, equities analysts expect that Omnicell, Inc. will post $1.31 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Omnicell, Inc. (OMCL) VP Sells 20,719 Shares of Stock” was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/omnicell-inc-omcl-vp-sells-1056254-62-in-stock-updated/1408893.html.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its position in shares of Omnicell by 79.7% in the first quarter. Bank of America Corp DE now owns 202,466 shares of the company’s stock valued at $8,231,000 after buying an additional 89,817 shares during the last quarter. First National Bank of Omaha acquired a new position in Omnicell during the first quarter valued at approximately $865,000. Parametric Portfolio Associates LLC raised its position in Omnicell by 4.9% in the first quarter. Parametric Portfolio Associates LLC now owns 145,279 shares of the company’s stock valued at $5,906,000 after buying an additional 6,786 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Omnicell during the fourth quarter valued at approximately $788,000. Finally, Nationwide Fund Advisors raised its position in Omnicell by 0.9% in the first quarter. Nationwide Fund Advisors now owns 253,955 shares of the company’s stock valued at $10,323,000 after buying an additional 2,224 shares during the last quarter. Institutional investors and hedge funds own 96.35% of the company’s stock.
A number of brokerages have commented on OMCL. BidaskClub downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reaffirmed a “hold” rating and set a $40.00 target price on shares of Omnicell in a research note on Sunday, July 30th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $47.00 target price on shares of Omnicell in a research note on Tuesday, July 25th. Dougherty & Co lifted their target price on shares of Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Craig Hallum lifted their target price on shares of Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $49.00.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with our FREE daily email newsletter.